Company to share updates at the AACR and ASGCT annual meetings BOSTON--(BUSINESS WIRE)--Strand Therapeutics Inc., the programmable mRNA company developing curative therapies for cancer and beyond, ...

Company’s NSCLC drug program is focused on overcoming both mutational and non-mutational resistance to 3 rd-generation EGFR inhibitors and outperforms other investigational 4 th-generation inhibitors ...